Current anticancer agents do not greatly differentiate between cancerous and normal cells
leading to systemic toxicity and adverse effects. The systemic application of the conventional
drugs often causes severe side effects in other tissues, which greatly limits the maximal
allowable dose of the drug. Cancer nanotherapeutics are rapidly progressing and are being
implemented to solve several limitations of conventional drug delivery systems such as
nonspecific biodistribution and targeting, lack of water solubility, poor bioavailability, and low …